CNSP

CNS Pharmaceuticals Inc. (CNSP) | Rumor.io

CNS Pharmaceuticals

CNSP

Attention (50-day avg)0%

Attention rank (50-day avg)#4,279

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization7.5M

Earnings per share-15.4

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-15.9M

Social

What share of all stock conversation is about CNSP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% -0.01

May 14

CNS Pharmaceuticals, Inc. (CNSP) reported first-quarter 2026 financial results, highlighting strategic transformation progress.
The company is seeking an AD/Director, Business Development to support in-licensing, diligence, valuation, and transaction execution as it builds a high-value pipeline.
NovaRed Mining's 39,726 acres in BC and deep targets beneath Wilmac are considered game-changers, with potential for significant technical strides.

Generated by AI

Sentiment

Of the messages about CNSP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	91.15% +4.82
Bearish	—	—	—	8.85% -4.82

Bullish· May 5

$CNSP has shown significant gains, with a 200%+ increase off a dilution/private placement catalyst, indicating potential for further price appreciation.
The company's recent private placement of $22.5 million from institutional investors is a major positive, improving its survival and enabling a strategy shift to acquire new clinical-stage assets and build a new pipeline.
$CNSP is likely to experience a price pump in the near future, with potential for a breakout above its previous PM high, driven by strong demand and institutional backing.

Bearish· May 5

$CNSP is at risk of a massive selloff due to a sudden loss of buying interest.
The company's warrant holders may artificially pump the stock to exercise their warrants.
$CNSP's price is likely to drop to $4-5, with a possible squeeze imminent.

Generated by AI

Topics

Of the messages about CNSP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	52.02%
Analysts	—	—	—	4.36%
Controversies	—	—	—	0.16%
Earnings	—	—	—	0.16%
Macro	—	—	—	2.42%
Technical Analysis	—	—	—	40.87%

Announcements· May 5

CNS Pharmaceuticals, Inc. (CNSP) raised approximately $22.5 million in a private placement from institutional investors, with the deal being oversubscribed due to strong demand.
The funds will be used to acquire new clinical-stage assets, build a new pipeline, and fund operations, marking a strategic shift away from failed or struggling legacy programs.
Institutional backing from healthcare funds, including ADAR1 and Ikarian, provides validation for CNS Pharmaceuticals' efforts to reinvent the company and move towards a more promising future.

Technical Analysis· May 4

The stock price of CNSP has had a significant run, with a 300% spike, and is currently trading above the 20-day and 50-day moving averages.
The stock has formed a clean consolidation structure, with printing higher lows, and has a strong support level at $8 and a resistance level at $10.
The 1-month outlook for CNSP suggests a base scenario of consolidation between $2.13 and $2.60, with a potential breakout above $2.60 opening a move toward $3.00-$3.50.

Generated by AI

Community

Of the messages about CNSP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	36.18%
Newcomers	—	—	100%	63.82%

Regulars· May 4

$CNSP has been experiencing a moderate green day, with the stock price showing a weird price action, leading to conservative trading.
The stock's structure is intact for bounce scalps above $8.00, but under $8.00, the intraday structure is compromised, making it difficult to expect huge moves.
The recent private placement financing of $22.5 million is expected to accelerate CNS Pharmaceuticals' expansion into neurology and oncology, with the company specializing in building a higher-value pipeline.

Newcomers· May 6

Market capitalization for CNS Pharmaceuticals, Inc. ($CNSP) is around $82M at $7 per share, considering the recent PIPE deal and pro forma share count.
The company's pre-deal assets and equity are $8.6M and $4.5M, respectively, with a 2025 operating cash burn of $13.8M.
New short positions in CNS Pharmaceuticals, Inc. ($CNSP) can be considered, especially with the recent price movements and the company's cash shell status with no new asset announced yet.

Generated by AI

Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" SegmentAccess the segment hereHOUSTON, TX / ACCESS Newswire / September 1, 2026 / (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment.Dylan Wenke, Chief Business Officer of CNS Pharmaceuticals, provided an update on

28d agoYahoo! Finance Canada

CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference

Video webcast now available hereHOUSTON, TX / ACCESS Newswire / August 27, 2026 / (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in the Virtual Investor "Why Now" on-demand conference.Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's strategic transformation that is being built on the strength of

1mo agoYahoo Finance

CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock

1mo agoInvesting.com

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation

Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline HOUSTON, TX / ACCESS Newswire / August 12, ...

1mo agoYahoo Finance

Also Discussed

Investors talking about CNSP also mention

#	Name	Attention
1	Cardio Diagnostics Holdings, Inc.CDIO	0%0
2	Xilio Therapeutics, Inc.XLO	0%0
3	GlucoTrack Inc.GCTK	0%0
4	Ocean Biomedical Inc.OCEA	0%0
5	Aclarion, Inc.ACON	0%0
6	Lichen International Ltd.LICN	0%new
7	Allarity Therapeutics Inc.ALLR	0%-0.01
8	Expion360 Inc.XPON	0%0
9	ZCAR - Zoomcar Holdings, Inc.	——
10	SOBR Safe, Inc.SOBR	0%0

CNS Pharmaceuticals Inc.

Healthcare
Biotechnology

CNS Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive cancers of the brain and central nervous system. Its current work centers on advancing anti-cancer drug candidates designed to address high-unmet-need diseases such as glioblastoma and other malignant brain tumors. The company’s pipeline includes investigational compounds such as berubicin and other neurology and oncology assets, reflecting its emphasis on treatments that can reach and act within the central nervous system. CNS Pharmaceuticals Inc. operates in the specialized oncology segment of the pharmaceutical market, where drug development is shaped by the challenges of treating tumors protected by the blood-brain barrier. The company is based in Houston, Texas, and its role in the market is to develop novel hospital- and specialist-directed treatment options for severe brain and CNS cancers.

Website

Location

2100 West Loop South

Houston, TX, 77027

United States

Social

What share of all stock conversation is about CNSP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% -0.01

May 14

CNS Pharmaceuticals, Inc. (CNSP) reported first-quarter 2026 financial results, highlighting strategic transformation progress.
The company is seeking an AD/Director, Business Development to support in-licensing, diligence, valuation, and transaction execution as it builds a high-value pipeline.
NovaRed Mining's 39,726 acres in BC and deep targets beneath Wilmac are considered game-changers, with potential for significant technical strides.

Generated by AI

Sentiment

Of the messages about CNSP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	91.15% +4.82
Bearish	—	—	—	8.85% -4.82

Bullish· May 5

$CNSP has shown significant gains, with a 200%+ increase off a dilution/private placement catalyst, indicating potential for further price appreciation.
The company's recent private placement of $22.5 million from institutional investors is a major positive, improving its survival and enabling a strategy shift to acquire new clinical-stage assets and build a new pipeline.
$CNSP is likely to experience a price pump in the near future, with potential for a breakout above its previous PM high, driven by strong demand and institutional backing.

Bearish· May 5

$CNSP is at risk of a massive selloff due to a sudden loss of buying interest.
The company's warrant holders may artificially pump the stock to exercise their warrants.
$CNSP's price is likely to drop to $4-5, with a possible squeeze imminent.

Generated by AI

Topics

Of the messages about CNSP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	52.02%
Analysts	—	—	—	4.36%
Controversies	—	—	—	0.16%
Earnings	—	—	—	0.16%
Macro	—	—	—	2.42%
Technical Analysis	—	—	—	40.87%

Announcements· May 5

CNS Pharmaceuticals, Inc. (CNSP) raised approximately $22.5 million in a private placement from institutional investors, with the deal being oversubscribed due to strong demand.
The funds will be used to acquire new clinical-stage assets, build a new pipeline, and fund operations, marking a strategic shift away from failed or struggling legacy programs.
Institutional backing from healthcare funds, including ADAR1 and Ikarian, provides validation for CNS Pharmaceuticals' efforts to reinvent the company and move towards a more promising future.

Technical Analysis· May 4

The stock price of CNSP has had a significant run, with a 300% spike, and is currently trading above the 20-day and 50-day moving averages.
The stock has formed a clean consolidation structure, with printing higher lows, and has a strong support level at $8 and a resistance level at $10.
The 1-month outlook for CNSP suggests a base scenario of consolidation between $2.13 and $2.60, with a potential breakout above $2.60 opening a move toward $3.00-$3.50.

Generated by AI

Community

Of the messages about CNSP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	36.18%
Newcomers	—	—	100%	63.82%

Regulars· May 4

$CNSP has been experiencing a moderate green day, with the stock price showing a weird price action, leading to conservative trading.
The stock's structure is intact for bounce scalps above $8.00, but under $8.00, the intraday structure is compromised, making it difficult to expect huge moves.
The recent private placement financing of $22.5 million is expected to accelerate CNS Pharmaceuticals' expansion into neurology and oncology, with the company specializing in building a higher-value pipeline.

Newcomers· May 6

Market capitalization for CNS Pharmaceuticals, Inc. ($CNSP) is around $82M at $7 per share, considering the recent PIPE deal and pro forma share count.
The company's pre-deal assets and equity are $8.6M and $4.5M, respectively, with a 2025 operating cash burn of $13.8M.
New short positions in CNS Pharmaceuticals, Inc. ($CNSP) can be considered, especially with the recent price movements and the company's cash shell status with no new asset announced yet.

Generated by AI

CNS Pharmaceuticals

Social

May 14

Sentiment

Bullish· May 5

Bearish· May 5

Topics

Announcements· May 5

Technical Analysis· May 4

Community

Regulars· May 4

Newcomers· May 6

News

CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth

CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference

CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation

Also Discussed

CNS Pharmaceuticals Inc.

Company Information

Location

News

CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth

CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference

CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation

Also Discussed

Social

May 14

Sentiment

Bullish· May 5

Bearish· May 5

Topics

Announcements· May 5

Technical Analysis· May 4

Community

Regulars· May 4

Newcomers· May 6